Page 121 - 《中国药房》2021年第9期
P. 121
能由相邻细胞平移填充,因此保护 RPE 细胞至关重要。 [ 6 ] DATTA S,CANO M,EBRAHIMI K,et al. The impact of
RPE 细胞损伤的主要诱因包括脂褐素积聚造成的炎症 oxidative stress and inflammation on RPE degeneration in
反应以及光辐射、吞噬功能高能代谢产生ROS造成的氧 non-neovascular AMD[J]. Prog Retin Eye Res,2017,60:
化应激损伤 。不同结构母核黄酮对于 AMD 防治作用 201-218.
[1]
的分子机制各不相同,总的来说可以概括为以下几个方 [ 7 ] EVANS J R,LAWRENSON J G. Antioxidant vitamin and
mineral supplements for slowing the progression of age-re-
面:(1)通过调节包括 TLR4/NF-κB、IL-6/JAK2/STAT3、
lated macular degeneration[J]. Cochrane Database Syst
MAPK 等 多 种 信 号 通 路 ,调 控 TNF-α 、IL-6、IL-8、
Rev,2017,7(7):CD000254.
MCP-1、MMP-9、ICAM-1 等多种炎症因子基因表达,抑
[ 8 ] VANDERBEEK B L,ZACKS D N,TALWAR N,et al.
制炎症反应发生;(2)基于黄酮母核 B 环的多羟基结构
Role of statins in the development and progression of
的抗氧化作用,能够直接中和细胞内局部高浓度 ROS,
age-related macular degeneration[J]. Retina,2013,33(2):
同时还可以直接激活 Nrf2/ARE 信号通路,调控 HO-1、 414-422.
NQO-1、GCLM、GCLC、SOD、GSH 等抗氧化基因表达; [ 9 ] GEHLBACH P,LI T J,HATEF E. Statins for age-related
(3)通过调控 PI3K 以及 HIF-1α/VEGF/VEGFR2 等信号 macular degeneration[J]. Cochrane Database Syst Rev,
通路,抑制VEGF表达,进而抑制CNV生成。 2016,2(2):CD006927.
目前,我国已上市的用于治疗 AMD 或眼底血管病 [10] HOSTETLER G L,RALSTON R A,SCHWARTZ S J.
变的黄酮类药物包括曲克芦丁(3′,4′,7-三羟乙基芸香 Flavones:food sources,bioavailability,metabolism,and
苷)、七叶洋地黄双苷滴眼液(洋地黄苷和七叶亭苷)和 bioactivity[J]. Adv Nutr,2017,8(3):423-435.
递法明片(欧洲越橘花青苷和β-胡萝卜素)等。目前对 [11] FARHADI F,KHAMENEH B,IRANSHAHI M. Antibac-
于黄酮的研究大多数仍处于实验阶段,仅有少数应用于 terial activity of flavonoids and their structure-activity re-
lationship:an update review[J]. Phytother Res,2019,33
临床,可能与该类化合物水难溶性、生物利用度低相关,
(1):13-40.
而这种现象主要是由黄酮平面结构的π-π堆积和分子间
[12] RAFFA D,MAGGIO B,RAIMONDI M V,et al. Recent
氢键导致的 [48-49] 。但也有研究表明,花色素型黄酮口服
discoveries of anticancer flavonoids[J]. Eur J Med Chem,
给药后可通过血-视网膜屏障,在眼底的血药浓度与静
2017,142:213-228.
脉给药和腹腔给药时相当 。另外值得注意的是,黄酮
[50]
[13] YAN T,BI H,WANG Y. Wogonin modulates hydropero-
可能带来的潜在DNA损伤不容忽视 [51-52] 。因此,将来应 xide-induced apoptosis via PI3K/Akt pathway in retinal
从改善黄酮水溶性、寻找合适的糖配体或开发新型眼内 pigment epithelium cells[J]. Diagn Pathol,2014,9:154.
给药剂型等方面进行开发及结构优化,以促进其更好地 [14] CHEN C,GUO D,LU G. Wogonin protects human retinal
应用于临床眼科疾病的治疗。 pigment epithelium cells from LPS-induced barrier dys-
参考文献 function and inflammatory responses by regulating the
[ 1 ] VAN LOOKEREN CAMPAGNE M,LECOUTER J,YAS- TLR4/NF-kappaB signaling pathway[J]. Mol Med Rep,
PAN B L,et al. Mechanisms of age-related macular dege- 2017,15(4):2289-2295.
neration and therapeutic opportunities[J]. J Pathol,2014, [15] HYTTI M,PIIPPO N,KORHONEN E,et al. Fisetin and
232(2):151-164. luteolin protect human retinal pigment epithelial cells
[ 2 ] SONG P,DU Y,CHAN K Y,et al. The national and sub- from oxidative stress-induced cell death and regulate in-
national prevalence and burden of age-related macular de- flammation[J]. Sci Rep,2015,5:17645.
generation in China[J]. J Glob Health,2017,7(2): [16] LIU J H,WANN H,CHEN M M,et al. Baicalein signifi-
020703. cantly protects human retinal pigment epithelium cells
[ 3 ] WONG W L,SU X,LI X,et al. Global prevalence of age- against H2O2 induced oxidative stress by scavenging reac-
related macular degeneration and disease burden projec- tive oxygen species and downregulating the expression of
tion for 2020 and 2040:a systematic review and meta- matrix metalloproteinase-9 and vascular endothelial
analysis[J]. Lancet Glob Health,2014,2(2):e106-e116. growth factor[J]. J Ocul Pharmacol Ther,2010,26(5):
[ 4 ] FLAXMAN S R,BOURNE R R,RESNIKOFF S,et al. 421-429.
Global causes of blindness and distance vision impair- [17] CHAO H M,CHUANG M J,LIU J H,et al. Baicalein pro-
ment 1990-2020:a systematic review and meta-analy- tects against retinal ischemia by antioxidation,antiapopto-
sis[J]. Lancet Glob Health,2017,5(12):e1221-e1234. sis,downregulation of HIF-1alpha,VEGF,and MMP-9
[ 5 ] ARMSTRONG R A,MOUSAVI M. Overview of risk fac- and upregulation of HO-1[J]. J Ocul Pharmacol Ther,
tors for age-related macular degeneration(AMD)[J]. J 2013,29(6):539-549.
Stem Cells,2015,10(3):171-191. [18] ZOU Y,CHIOU G C. Apigenin inhibits laser-induced cho-
中国药房 2021年第32卷第9期 China Pharmacy 2021 Vol. 32 No. 9 ·1135 ·